Zai Lab (HKEX:9688), (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to meet the needs of patients across a broad range of diseases, including oncology, autoimmune disorders, and infectious diseases. The company emphasizes research and collaboration, aiming to bring cutting-edge treatments to underserved populations. Through its projects, Zai Lab endeavors to push the boundaries of medical science, striving to improve outcomes and enhance the quality of life for patients worldwide. Its objectives center around expanding its product portfolio, advancing its clinical trials, and fostering partnerships to accelerate the global availability of its therapeutic solutions.